FES

Across TCGA pan-cancer cohorts, FES Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FES data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher FES Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FES expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, LIHC, and COAD are the cancer types where FES Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
LIHC	DFS	Median	All	0.053	0.553	<.001	12	view →
COAD	OS	Median	All	0.100	0.669	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
BRCA	DFS	Median	All	0.205	0.527	.014	4	view →
SKCM	OS	Median	III,IV	1.000	0.379	.032	3	view →
LGG	DFS	Median	All	0.593	0.825	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FES–ESCA (DFS)

Open the ESCA breakdown →